The development of therapies and vaccines for human hepatropic pathogens requires
robust model systems that enable the study of host-pathogen interactions. However, in vitro …

Engineered liver systems come in a variety of platform models, from 2-dimensional
cocultures of primary human hepatocytes and stem cell–derived progeny, to 3-dimensional …

With more than 240 million people infected, hepatitis B virus (HBV) is a major health
concern. The inability to mimic the complexity of the liver using cell lines and regular primary …

Hepatitis B virus (HBV) chronically infects 400 million people worldwide and is a leading
driver of end-stage liver disease and liver cancer. Research into the biology and treatment of …

Hepatitis C virus (HCV) remains a major public health problem, affecting approximately 130
million people worldwide. HCV infection can lead to cirrhosis, hepatocellular carcinoma, and …

In vitro models of the human liver are important for the following:(1) mitigating the risk of drug-
induced liver injury to human beings,(2) modeling human liver diseases,(3) elucidating the …

The Plasmodium liver stage is an attractive target for the development of antimalarial drugs
and vaccines, as it provides an opportunity to interrupt the life cycle of the parasite at a …

Hepatitis B virus (HBV) remains a major global health problem with 257 million chronically
infected individuals worldwide, of whom approximately 20 million are co‐infected with …

Chronic infection with hepatitis B virus (HBV) continues to be a major health problem
affecting about 400 million people worldwide. The narrow species tropism of HBV has …

A paucity of versatile small animal models of hepatitis B virus (HBV) and hepatitis C virus
(HCV) infection has been an impediment to both furthering understanding of virus biology …